Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial)

Publication | Closed Access

DOI

Citations

References

2014

Year

Florian Kocher, Andreas Pircher, Andrea Mohn-Staudner, Franz Romeder, W. Duller, M Steinmaurer, Josef Eckmayr, Thomas Schmid, Wolfgang Hilbe, Michael Fiegl,

Lung Cancer

Tax-at 1.203Surgical OncologyOncologyMetronomic TherapyClinical TrialsAdjuvant Docetaxel TherapyPharmacotherapyCancer TreatmentRadiation OncologyMedicineCancer ChemotherapyLung CancerNsclc Stage IiRadiologyHealth Sciences